PTC/SB/08a (08-03)
Approved for use through 07/31/2006 OM5 0651-0201
U.S. Patient and Trademask Office; U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it contains a valid OM6 control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10576159	
	Filing Date			
	First Named Inventor	ALLON GUEZ		
	Art Unit		2121	
	Examiner Name			
	Attorney Docket Numb	er	DREX-1007US	

		U.S.PATENTS				Remove	
Examiner Initial*	Cite No Patent Number		Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	
	1	5428704		1995-06-27	LEBBY		
	2	5887089		1999-03-23	DEACON		
	3	5977567		1999-11-02	VERDIELL		
	4	6014396		2000-01-11	OSINSKI		
	5	6243508		2001-06-05	JEWEL		
	6	6325551		2001-12-04	WILLIAMSON		
	7	6359681		2002-03-19	HOUSAND		
	8	6376268		2002-04-23	VERDIELL		

Filing Date INFORMATION DISCLOSURE First Named Inventor ALLON GUEZ STATEMENT BY APPLICANT Art I Init 2121 (Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number DREY-1007US 6736553 2004-05-18 STIFHI If you wish to add additional U.S. Patent citation information please click the Add button. Add U.S.PATENT APPLICATION PUBLICATIONS Pages, Columns, Lines where Examiner Cite Kind Publication Name of Patentee or Applicant Publication Number Relevant Passages or Relevant Initial* Nο Code¹ Date of cited Document Figures Appear 20020062170 2002-05-23 SKLINES 2 20030201462 2003-10-30 POMMER If you wish to add additional U.S. Published Application citation information please click the Add button Add FOREIGN PATENT DOCUMENTS Pages,Columns,Lines Name of Patentee or Examiner Cite Foreign Document Country Kind Publication where Relevant Applicant of cited T5 Initial* Nο Number³ Code2 i Code4 Date Passages or Relevant Document Figures Appear Add If you wish to add additional Foreign Patent Document citation information please click the Add button Remove NON-PATENT LITERATURE DOCUMENTS

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

T5

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

If you wish to add additional non-patent literature document citation information please click the Add button Add

publisher, city and/or country where published.

Application Number

10578159

EES WAS 101

Examiner Cite

Initials* No.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10576159
	Filing Date		
	First Named Inventor	ALLC	N GUEZ
	Art Unit		2121
	Examiner Name		
	Attorney Docket Numb	er	DREX-1007US

EXAMINER SIGNATURE			
Examiner Signature		Date Considered	
ACCUMULED IN 18 of the second			

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

16ex fix Codes of USPTO Peters Documents at yeary USPTO_CGI/or MEPS 90.04. 2 feller office that issued the document, by the Involved rook (WIPO Standard ST3.) 3 for Just purpose peter for Lournesh, the ordication of the year of the register or surpressed the sent and there of the patent document, 4 fixed of document by the appropriate symbols as addicated on the document under WIPO Standard ST.16 if possible, 3 Applicant is to place a check mark here if English targuages the resistance is attached.

Attorney Docket Number C

DREY-1007US

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. Sec 37 CFR 197(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/KEVIN J. DUNLEAVY/	Date (YYYY-MM-DD)	2006-09-28
Name/Print	KEVIN I DUNI FAVV	Registration Number	32 024

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet of sciences, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via self or in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.